Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ONO4819

Known as: ONO-4819 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Heptanoates

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Prostaglandin E(2) receptor EP(4)-selective agonist (ONO-4819) increases bone formation by modulating mesenchymal cell differentiation.
Prostaglandin E(2) (PGE(2)) positively regulates bone resorption and formation mainly mediated through the EP(4) receptor, a… Expand
2008
2008
Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation
 
2007
2007
Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation.
Bone morphogenetic proteins (BMPs) were originally isolated based on their ability to induce ectopic cartilage and bone formation… Expand
2006
2006
Effects of a prostaglandin EP4 agonist, ONO-4819, and risedronate on trabecular microstructure and bone strength in mature ovariectomized rats.
The effects of a prostaglandin EP4 agonist, ONO-4819, and risedronate, a representative anti-resorptive drug, on trabecular… Expand
Highly Cited
2005
Highly Cited
2005
Effect of a selective agonist for prostaglandin E receptor subtype EP4 (ONO-4819) on the cortical bone response to mechanical loading.
The influence of a selective agonist for prostaglandin E receptor subtype EP4 (ONO-4819) on the bone response to mechanical… Expand
2005
2005
Prostaglandin D2 and prostaglandin E2 accelerate the recovery of cutaneous barrier disruption induced by mechanical scratching in mice.
The role of prostaglandins in mechanical scratching-induced cutaneous barrier disruption in mice was investigated. Skin… Expand
2005
2005
Prostaglandin EP4 receptor agonist augments fixation of hydroxyapatite-coated implants in a rat model of osteoporosis.
The reduced stability of hydroxyapatite (HA)-coated implants in osteopenic conditions is considered to be a major problem. We… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2004
2004
A prostanoid receptor EP4 agonist enhances ectopic bone formation induced by recombinant human bone morphogenetic protein-2.
The anabolic effects of prostaglandin E(2) on bone are effected through the activation of EP4, a G protein-coupled receptor. In… Expand
2004
2004
An EP4 Receptor Agonist Prevents Indomethacin-Induced Closure of Rat Ductus Arteriosus In Vivo
Indomethacin exerts a strong tocolytic effect by suppressing uterine contractions mediated by prostaglandins. However… Expand
  • figure 3
  • figure 1
  • figure 4
  • figure 2
  • table 1
2004
2004
Up-regulation of lymphocytic cholinergic activity by ONO-4819, a selective prostaglandin EP4 receptor agonist, in MOLT-3 human leukemic T cells.
We used a selective EP4 receptor agonist, ONO-4819, and a human leukemic T cell line MOLT-3 cells, which express all four… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE